TAM Receptor

TAM receptor inhibitors act on Tyro3, Axl and Mer, three receptor tyrosine kinases in immune control. Axl was described in 1991 as a transforming gene isolated from primary human myeloid leukemia cells. The receptors bind the ligands growth arrest-specific 6 (Gas6) and protein S, and they mediate clearance of apoptotic cells by phagocytes. TAM signaling also limits inflammatory responses of dendritic cells and macrophages, as reviewed in 2008. R428 and dubermatinib are Axl inhibitors, whereas UNC569 targets Mer and LDC1267 acts on all three family members. Cabozantinib, a multikinase inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and the hepatocyte growth factor receptor (c-Met), also inhibits Axl.

Items 51-64 of 64

  • AXL-IN-15
    Cat. No.
    A84763

    AXL-IN-15

    AXL-IN-15 is a highly potent inhibitor of the Axl receptor tyrosine kinase, exhibiting Ki and IC50 values of less than 1 nM. This compound is valuable for research focused on cancer biology, particularly in studies investigating Axl's role in tumor progression and metastasis. AXL-IN-15 can aid in elucidating the molecular mechanisms underlying Axl-mediated signaling pathways and their implications in various malignancies.

    Out of stock

    All 3 sizes
  • Axl-IN-7
    Cat. No.
    A84764

    Axl-IN-7

    Axl-IN-7 is a potent inhibitor of the AXL receptor tyrosine kinase. This compound demonstrates significant activity in targeting AXL-mediated signaling pathways, making it valuable for investigating AXL-related diseases, including various cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors. Additionally, Axl-IN-7 has potential applications in research focused on renal diseases, immune system disorders, and cardiovascular conditions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • MerTK/Axl-IN-1
    Cat. No.
    A84765

    MerTK/Axl-IN-1

    MerTK/Axl-IN-1 is a highly selective dual inhibitor targeting MerTK and Axl receptors, demonstrating potent inhibitory activity with IC50 values of 4.2 nM and 8.8 nM in Ba/F3 cells, and 0.2 nM and 0.9 nM in HTRF assays. This compound effectively inhibits phosphorylated MerTK (pMerTK) in vivo, indicating its utility in biological research. With a prolonged half-life and favorable oral bioavailability, MerTK/Axl-IN-1 is suitable for studies in cancer biology and therapeutic development aimed at disruptions in MerTK and Axl signaling pathways.

    5 mg
    $1,255.00
    10 mg
    $1,930.00
    All 4 sizes
  • Axl-IN-19
    Cat. No.
    A84766

    Axl-IN-19

    Axl-IN-19 is a selective inhibitor of AXL, a membrane-bound receptor tyrosine kinase, exhibiting an IC50 of 5.3 nM and a cellular KD of 6.8 nM. This compound demonstrates favorable pharmacokinetic properties in rats, characterized by low clearance and moderate bioavailability. Axl-IN-19 is primarily utilized in cancer research to explore the role of AXL signaling in tumor progression and metastasis.

    Out of stock

    All 3 sizes
  • MerTK-IN-1
    Cat. No.
    A84767

    MerTK-IN-1

    MerTK-IN-1 is an inhibitor of the MerTK receptor, a critical target in the regulation of tumor-associated macrophages (TAMs). This compound demonstrates the ability to effectively bind to MerTK in vivo, providing valuable insight into immune modulation in tumor microenvironments. MerTK-IN-1 is suitable for research applications focused on cancer immunotherapy and the role of macrophages in tumor progression.

    Out of stock

    All 3 sizes
  • Anticancer agent 109
    Cat. No.
    A84768

    Anticancer agent 109

    Anticancer agent 109 is a Gas6/Axl inhibitor that demonstrates significant anti-cancer activity. This compound effectively downregulates the expression of Gas6 and Axl, which in turn reduces the activation of p-PI3K and p-AKT in cancer cells. Anticancer agent 109 induces G1 phase cell cycle arrest and promotes apoptosis, leading to substantial inhibition of tumor growth in nude mouse models. This reagent is suitable for research focused on cancer biology and therapeutic development targeting the Gas6/Axl signaling pathway.

    Out of stock

    All 3 sizes
  • UNC9435
    Cat. No.
    A84769

    UNC9435

    UNC9435 is a dual inhibitor of TYRO3 and MERTK, exhibiting IC50 values of 3.7 nM and 1.1 nM, respectively. This compound has been shown to significantly reduce colony formation in non-small cell lung cancer cultures, indicating its potential as a therapeutic agent in cancer research. UNC9435 may also serve as a useful tool for studying the role of TYRO3 and MERTK in various biological processes and disease mechanisms.

    Out of stock

    All 3 sizes
  • Axl-IN-3
    Cat. No.
    A84770

    Axl-IN-3

    Axl-IN-3 is a selective inhibitor of the AXL kinase, demonstrating potent activity with an IC50 of 41.5 nM. This compound has shown minimal inhibition of other kinases, making it an ideal choice for studies focused on AXL-mediated signaling pathways. Axl-IN-3 is suitable for research applications involving cancer biology, immune modulation, and therapeutic resistance studies.

    Out of stock

    All 3 sizes
  • UNC8969
    Cat. No.
    A84771

    UNC8969

    UNC8969 is a dual inhibitor targeting MERTK and AXL, exhibiting IC50 values of 1.1 ± 0.8 nM for MERTK and 5.3 ± 2.7 nM for AXL. With a half-life (T1/2) of 7.3 hours following intravenous administration at 5 mg/kg in mice, UNC8969 demonstrates significant biological activity. This compound is valuable for research applications focused on cancer biology, particularly in studies investigating the roles of MERTK and AXL in tumor progression and immune modulation.

    Out of stock

    All 3 sizes
  • AXL-IN-14
    Cat. No.
    A84772

    AXL-IN-14

    AXL-IN-14 is a highly potent, orally bioavailable inhibitor of AXL, exhibiting an impressive IC50 value of 0.8 nM. This compound effectively disrupts Gas6/AXL-mediated cell migration and invasion while reducing the expression levels of phospho-AXL and phospho-AKT proteins. AXL-IN-14 demonstrates significant anti-tumor activity, making it a valuable tool for research in cancer therapeutics and metastasis studies.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • Axl-IN-5
    Cat. No.
    A84773

    Axl-IN-5

    Axl-IN-5 is a selective inhibitor of AXL, exhibiting an IC50 of 283 nM. This compound demonstrates significant anticancer activity, making it a valuable tool for research in cancer biology. Axl-IN-5 can be utilized to study the role of AXL signaling in tumor progression and to investigate potential therapeutic strategies targeting the AXL pathway in various malignancies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • (Z)-S49076 hydrochloride
    Cat. No.
    A84774

    (Z)-S49076 hydrochloride

    (Z)-S49076 hydrochloride is a potent inhibitor of MET and AXL, effectively disrupting their downstream signaling pathways. This compound demonstrates significant biological activity by inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. Additionally, (Z)-S49076 hydrochloride addresses resistance mechanisms associated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in Erlotinib-resistant cell lines. It is a valuable tool for research in non-small cell lung cancer (NSCLC).

    1 mg
    $100.00
    5 mg
    $315.00
    All 4 sizes
  • Denfivontinib hydrochloride
    Cat. No.
    A84775

    Denfivontinib hydrochloride

    Synonyms: G-749 hydrochloride

    Denfivontinib hydrochloride is an AXL inhibitor that exerts synergistic antitumor effects when used in combination with the PD-1 inhibitor Pembrolizumab. This compound enhances the NOD-like receptor pathway, facilitating the formation of the NLRP3 inflammasome. Its unique mechanism of action makes it a valuable tool for cancer research, particularly in studying immune modulation and tumor progression.

    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes
  • ER-851
    Cat. No.
    A84776

    ER-851

    ER-851 is a selective inhibitor of AXL with an IC50 of 100 nM, demonstrating potent oral bioactivity. It has been shown to exhibit antitumor effects, making it a valuable compound for research in cancer biology and therapeutic development. Its selectivity and efficacy position ER-851 as a critical tool for studying AXL's role in tumor progression and metastasis.

    Out of stock

    All 3 sizes

Items 51-64 of 64

Added to your cart

View Cart Checkout

    Loading...